宫颈癌同步放化疗前后HPV DNA及TNF-α的变化  

Changes of HPV DNA and TNF-α levels in patients with advanced cervical cancer before and after concurrent chemoradiotherapy

作　　者：曾四元[1] 李隆玉[1] 李汉萍[1] 

机构地区：[1]江西省妇幼保健院肿瘤科,江西南昌330006

出　　处：《第四军医大学学报》2006年第18期1717-1719,共3页Journal of the Fourth Military Medical University

摘　　要：目的:观察中晚期宫颈癌患者同步放化疗治疗前、后宫颈分泌物HPV DNA及血清TNF-α含量的变化趋势.方法:采用第二代杂交捕获技术(HC-2)和双抗体夹心ABC-ELISA法检测30例中晚期宫颈癌患者(实验组)同步放化疗治疗前、后宫颈分泌物HPV DNA及血清TNF-α的含量,并与20例健康妇女作对照(健康对照组).结果:实验组治疗前宫颈分泌物HPV DNA阳性率为96.7%,显著高于健康对照组(10%);治疗后HPV DNA阳性率20%(P<0.01),转阴率为79.3%(23/29).实验组治疗前血清TNF-α含量为(134.15±77.99)pg/mL,治疗后为(113.14±79.99)pg/mL,均显著高于健康对照组(54.91±13.19)pg/mL,P<0.01.实验组治疗后血清TNF-α含量与治疗前比较无显著差异(P>0.05),但有下降趋势.结论:检测子宫颈癌患者宫颈分泌物HPVDNA及血清TNF-α的含量,可作为宫颈癌辅助诊断,判断治疗效果和预后的参考指标.AIM： To analyze the changing of HPV DNA in cervical secretions and serum TNF-α level in patients with advanced cervical cancer before and after concurrent ehemoradiotherapy. METHODS： The level of HPV DNA was tested by HC- 2 and TNF-α by ABC-ELISA in 30 patients with advanced cervical cancer （reseach group ） before and after chemoradiotherapy and 20 healthy women as the controls. RESULTS： The HPV infection rate before treatment（96.7% ） was higher than that after treatment （20%） and in normal controls （10%）. The negative conversion rate at the end of treatment was 79.3% （23/29）. The levels of serum TNF-α before and after chemoradiotherapy [ （ 134.15±77.99） and （ 113.14±79.99） pg/mL respectively] were both higher than that in normal controls[ （54.91±13.19 ） pg/mL, P 〈 0. 01 ]. Serum TNF-α levels had no signiificant difference between pre-treatment and post-treatment （ P 〉 0.05 ）, but a tendency of decreasing existed. CONCLUSION： The detection of HPV DNA in cervical secreations and serum TNF-α might be useful reference indexes for diagnosis and judging prognosis or curative effect.

关 键 词：中晚期宫颈癌 同步放化疗 HPV TNF—α 

分 类 号：R737.33[医药卫生—肿瘤]